Literature DB >> 23707558

Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice.

Vernon W Dolinsky1, Subhadeep Chakrabarti, Troy J Pereira, Tatsujiro Oka, Jody Levasseur, Donna Beker, Beshay N Zordoky, Jude S Morton, Jeevan Nagendran, Gary D Lopaschuk, Sandra T Davidge, Jason R B Dyck.   

Abstract

Resveratrol (RESV) is a polyphenol with pleiotropic effects that include reduction of oxidative stress and increased vascular nitric oxide (NO) production. However, whether or not RESV can prevent rises in blood pressure (BP) is controversial and remains to be firmly established. The purpose of this study was to determine whether RESV attenuates elevated BP and subsequent adaptive cardiac hypertrophy and to better understand the mechanisms involved. The spontaneously hypertensive rat (SHR) and the angiotensin (Ang)-II infused mouse were used as hypertensive models. Compared to a standard control diet, consumption of diets containing RESV by SHRs and Ang-II hypertensive mice, markedly prevented rises in systolic BP. In addition, flow-mediated vasodilation was significantly improved by RESV in SHRs. RESV also reduced serum and cardiac levels of the lipid peroxidation by-product, 4-hydroxy-2-nonenal in the hypertensive rodents and inhibited the production of superoxide in human-derived endothelial cells. Analysis of mesenteric arteries from SHRs and Ang-II infused mice demonstrated that RESV increased endothelial NO synthase (eNOS) phosphorylation by enhancing the LKB1/adenosine monophosphate (AMP)-activated protein kinase (AMPK) signal transduction pathway. Moreover, RESV reduced hypertrophic growth of the myocardium through reduced hemodynamic load and inhibition of the p70 S6 kinase pro-hypertrophic signaling cascade. Overall, we show that high dose RESV reduces oxidative stress, improves vascular function, attenuates high BP and prevents cardiac hypertrophy through the preservation of the LKB1-AMPK-eNOS signaling axis.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  4-hydroxy-2-nonenal; AMP-activated protein kinase; AMPK; Ang-II; BP; HNE; HUVEC; HW/TL; Hypertension; IVRT; IVS; LV; LV ejection fraction; LV posterior wall; LVEF; LVPW; Left ventricular hypertrophy; Lipid peroxide; NO; Nitric oxide; RESV; ROS; Resveratrol; SHR; Signal transduction; angiotensin-II; blood pressure; eNOS; endothelial nitric oxide synthase; heart weight/tibia length; human umbilical vein endothelial cell; intraventricular relaxation time; intraventricular septum; left ventricular; nitric oxide; reactive oxygen species; resveratrol; spontaneously hypertensive rat

Mesh:

Substances:

Year:  2013        PMID: 23707558     DOI: 10.1016/j.bbadis.2013.05.018

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  61 in total

1.  Resveratrol prevents pathological but not physiological cardiac hypertrophy.

Authors:  Vernon W Dolinsky; Carrie-Lynn M Soltys; Kyle J Rogan; Anita Y M Chan; Jeevan Nagendran; Shaohua Wang; Jason R B Dyck
Journal:  J Mol Med (Berl)       Date:  2014-11-15       Impact factor: 4.599

2.  Acute activation of endothelial AMPK surprisingly inhibits endothelium-dependent hyperpolarization-like relaxations in rat mesenteric arteries.

Authors:  Hui Chen; Paul M Vanhoutte; Susan W S Leung
Journal:  Br J Pharmacol       Date:  2019-07-04       Impact factor: 8.739

Review 3.  Antioxidant effects of resveratrol in the cardiovascular system.

Authors:  Ning Xia; Andreas Daiber; Ulrich Förstermann; Huige Li
Journal:  Br J Pharmacol       Date:  2016-05-06       Impact factor: 8.739

4.  Reprogramming Essential Hypertension: The Role of Resveratrol.

Authors:  Suttira Intapad
Journal:  Hypertension       Date:  2016-02-29       Impact factor: 10.190

Review 5.  Resveratrol supplementation: Where are we now and where should we go?

Authors:  Marta G Novelle; Devin Wahl; Carlos Diéguez; Michel Bernier; Rafael de Cabo
Journal:  Ageing Res Rev       Date:  2015-01-24       Impact factor: 10.895

Review 6.  Pharmacological Strategies to Retard Cardiovascular Aging.

Authors:  Irene Alfaras; Clara Di Germanio; Michel Bernier; Anna Csiszar; Zoltan Ungvari; Edward G Lakatta; Rafael de Cabo
Journal:  Circ Res       Date:  2016-05-13       Impact factor: 17.367

7.  Activation of AMPK in Human Placental Explants Impairs Mitochondrial Function and Cellular Metabolism.

Authors:  Daphne Landau; Maricela Haghiac; Judi Minium; Yelenna Skomorovska-Prokvolit; Virtu Calabuig-Navarro; Perrie O'Tierney-Ginn
Journal:  Reprod Sci       Date:  2018-05-22       Impact factor: 3.060

8.  AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism.

Authors:  Miranda M Sung; Beshay N Zordoky; Adam L Bujak; James S V Lally; David Fung; Martin E Young; Sandrine Horman; Edward J Miller; Peter E Light; Bruce E Kemp; Gregory R Steinberg; Jason R B Dyck
Journal:  Cardiovasc Res       Date:  2015-05-28       Impact factor: 10.787

9.  Angiotensin II-induced hypertension blunts thick ascending limb NO production by reducing NO synthase 3 expression and enhancing threonine 495 phosphorylation.

Authors:  Vanesa D Ramseyer; Agustin Gonzalez-Vicente; Oscar A Carretero; Jeffrey L Garvin
Journal:  Am J Physiol Renal Physiol       Date:  2014-11-05

10.  LKB1/AMPK pathway mediates resistin-induced cardiomyocyte hypertrophy in H9c2 embryonic rat cardiomyocytes.

Authors:  Peng Liu; Guan-Chang Cheng; Qun-Hui Ye; Yong-Zhi Deng; Lin Wu
Journal:  Biomed Rep       Date:  2016-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.